Autopsy report · NCT04242173

Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC

“Lack of Interest”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 1 year 11 months before it stopped.
• 3 participants enrolled.
• Results were posted on the registry 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Sponsor type

University, hospital or other

Conditions

Cutaneous Squamous Cell Carcinoma; Cutaneous Squamous Cell Carcinoma of the Head and Neck

Interventions

Cemiplimab-Rwlc

Participants

3

Sites

2

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.